Hyaluronic acid-conjugated lipoplexes for targeted delivery of siRNA in a murine metastatic lung cancer model

Thais Leite Nascimento, Hervé Hillaireau, Juliette Vergnaud, Melania Rivano, Claudine Deloménie, Delphine Courilleau, Silvia Arpicco, Jung Soo Suk, Justin S Hanes, Elias Fattal

Research output: Contribution to journalArticle

Abstract

We have investigated the impact of hyaluronic acid (HA)-coating on the targeting capacity of siRNA lipoplexes to CD44-overexpressing tumor cells. Cellular uptake and localization of HA-lipoplexes were evaluated by flow cytometry and fluorescence microscopy and both methods showed that these lipoplexes were rapidly internalized and localized primarily within the cytoplasm. Inhibition of luciferase expression on the A549-luciferase lung cancer cell line was achieved in vitro using an anti-Luc siRNA. 81% of luciferase gene expression inhibition was obtained in vitro with HA-lipoplexes at +/− ratio 2. In vivo, in a murine A549 metastatic lung cancer model, the treatment with HA-lipoplexes carrying anti-luciferase siRNA led to a statistically significant decrease of luciferase expression as opposed to progressive increase with non-modified lipoplexes or NaCl 0.9%. The reduction of the expression of luciferase mRNA tumor of mice treated with HA-lipoplexes supported the inhibition effect due to siRNA. These results highlight the potential of HA-lipoplexes in CD44-targeting siRNA delivery.

Original languageEnglish (US)
Pages (from-to)103-111
Number of pages9
JournalInternational Journal of Pharmaceutics
Volume514
Issue number1
DOIs
StatePublished - Nov 30 2016

Fingerprint

Hyaluronic Acid
Luciferases
Small Interfering RNA
Lung Neoplasms
Fluorescence Microscopy
Neoplasms
Flow Cytometry
Cytoplasm
Gene Expression
Cell Line
Messenger RNA

Keywords

  • A549
  • CD44
  • Hyaluronic acid
  • Lipoplexes
  • Luciferase
  • siRNA

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Leite Nascimento, T., Hillaireau, H., Vergnaud, J., Rivano, M., Deloménie, C., Courilleau, D., ... Fattal, E. (2016). Hyaluronic acid-conjugated lipoplexes for targeted delivery of siRNA in a murine metastatic lung cancer model. International Journal of Pharmaceutics, 514(1), 103-111. https://doi.org/10.1016/j.ijpharm.2016.06.125

Hyaluronic acid-conjugated lipoplexes for targeted delivery of siRNA in a murine metastatic lung cancer model. / Leite Nascimento, Thais; Hillaireau, Hervé; Vergnaud, Juliette; Rivano, Melania; Deloménie, Claudine; Courilleau, Delphine; Arpicco, Silvia; Suk, Jung Soo; Hanes, Justin S; Fattal, Elias.

In: International Journal of Pharmaceutics, Vol. 514, No. 1, 30.11.2016, p. 103-111.

Research output: Contribution to journalArticle

Leite Nascimento, T, Hillaireau, H, Vergnaud, J, Rivano, M, Deloménie, C, Courilleau, D, Arpicco, S, Suk, JS, Hanes, JS & Fattal, E 2016, 'Hyaluronic acid-conjugated lipoplexes for targeted delivery of siRNA in a murine metastatic lung cancer model', International Journal of Pharmaceutics, vol. 514, no. 1, pp. 103-111. https://doi.org/10.1016/j.ijpharm.2016.06.125
Leite Nascimento, Thais ; Hillaireau, Hervé ; Vergnaud, Juliette ; Rivano, Melania ; Deloménie, Claudine ; Courilleau, Delphine ; Arpicco, Silvia ; Suk, Jung Soo ; Hanes, Justin S ; Fattal, Elias. / Hyaluronic acid-conjugated lipoplexes for targeted delivery of siRNA in a murine metastatic lung cancer model. In: International Journal of Pharmaceutics. 2016 ; Vol. 514, No. 1. pp. 103-111.
@article{4cdda58cfd0d4db69a5670c57484dda6,
title = "Hyaluronic acid-conjugated lipoplexes for targeted delivery of siRNA in a murine metastatic lung cancer model",
abstract = "We have investigated the impact of hyaluronic acid (HA)-coating on the targeting capacity of siRNA lipoplexes to CD44-overexpressing tumor cells. Cellular uptake and localization of HA-lipoplexes were evaluated by flow cytometry and fluorescence microscopy and both methods showed that these lipoplexes were rapidly internalized and localized primarily within the cytoplasm. Inhibition of luciferase expression on the A549-luciferase lung cancer cell line was achieved in vitro using an anti-Luc siRNA. 81{\%} of luciferase gene expression inhibition was obtained in vitro with HA-lipoplexes at +/− ratio 2. In vivo, in a murine A549 metastatic lung cancer model, the treatment with HA-lipoplexes carrying anti-luciferase siRNA led to a statistically significant decrease of luciferase expression as opposed to progressive increase with non-modified lipoplexes or NaCl 0.9{\%}. The reduction of the expression of luciferase mRNA tumor of mice treated with HA-lipoplexes supported the inhibition effect due to siRNA. These results highlight the potential of HA-lipoplexes in CD44-targeting siRNA delivery.",
keywords = "A549, CD44, Hyaluronic acid, Lipoplexes, Luciferase, siRNA",
author = "{Leite Nascimento}, Thais and Herv{\'e} Hillaireau and Juliette Vergnaud and Melania Rivano and Claudine Delom{\'e}nie and Delphine Courilleau and Silvia Arpicco and Suk, {Jung Soo} and Hanes, {Justin S} and Elias Fattal",
year = "2016",
month = "11",
day = "30",
doi = "10.1016/j.ijpharm.2016.06.125",
language = "English (US)",
volume = "514",
pages = "103--111",
journal = "International Journal of Pharmaceutics",
issn = "0378-5173",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Hyaluronic acid-conjugated lipoplexes for targeted delivery of siRNA in a murine metastatic lung cancer model

AU - Leite Nascimento, Thais

AU - Hillaireau, Hervé

AU - Vergnaud, Juliette

AU - Rivano, Melania

AU - Deloménie, Claudine

AU - Courilleau, Delphine

AU - Arpicco, Silvia

AU - Suk, Jung Soo

AU - Hanes, Justin S

AU - Fattal, Elias

PY - 2016/11/30

Y1 - 2016/11/30

N2 - We have investigated the impact of hyaluronic acid (HA)-coating on the targeting capacity of siRNA lipoplexes to CD44-overexpressing tumor cells. Cellular uptake and localization of HA-lipoplexes were evaluated by flow cytometry and fluorescence microscopy and both methods showed that these lipoplexes were rapidly internalized and localized primarily within the cytoplasm. Inhibition of luciferase expression on the A549-luciferase lung cancer cell line was achieved in vitro using an anti-Luc siRNA. 81% of luciferase gene expression inhibition was obtained in vitro with HA-lipoplexes at +/− ratio 2. In vivo, in a murine A549 metastatic lung cancer model, the treatment with HA-lipoplexes carrying anti-luciferase siRNA led to a statistically significant decrease of luciferase expression as opposed to progressive increase with non-modified lipoplexes or NaCl 0.9%. The reduction of the expression of luciferase mRNA tumor of mice treated with HA-lipoplexes supported the inhibition effect due to siRNA. These results highlight the potential of HA-lipoplexes in CD44-targeting siRNA delivery.

AB - We have investigated the impact of hyaluronic acid (HA)-coating on the targeting capacity of siRNA lipoplexes to CD44-overexpressing tumor cells. Cellular uptake and localization of HA-lipoplexes were evaluated by flow cytometry and fluorescence microscopy and both methods showed that these lipoplexes were rapidly internalized and localized primarily within the cytoplasm. Inhibition of luciferase expression on the A549-luciferase lung cancer cell line was achieved in vitro using an anti-Luc siRNA. 81% of luciferase gene expression inhibition was obtained in vitro with HA-lipoplexes at +/− ratio 2. In vivo, in a murine A549 metastatic lung cancer model, the treatment with HA-lipoplexes carrying anti-luciferase siRNA led to a statistically significant decrease of luciferase expression as opposed to progressive increase with non-modified lipoplexes or NaCl 0.9%. The reduction of the expression of luciferase mRNA tumor of mice treated with HA-lipoplexes supported the inhibition effect due to siRNA. These results highlight the potential of HA-lipoplexes in CD44-targeting siRNA delivery.

KW - A549

KW - CD44

KW - Hyaluronic acid

KW - Lipoplexes

KW - Luciferase

KW - siRNA

UR - http://www.scopus.com/inward/record.url?scp=84995691217&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995691217&partnerID=8YFLogxK

U2 - 10.1016/j.ijpharm.2016.06.125

DO - 10.1016/j.ijpharm.2016.06.125

M3 - Article

C2 - 27863652

AN - SCOPUS:84995691217

VL - 514

SP - 103

EP - 111

JO - International Journal of Pharmaceutics

JF - International Journal of Pharmaceutics

SN - 0378-5173

IS - 1

ER -